Retatrutide (LY-3437943) Overview

Retatrutide, with its compound code LY-3437943, is an experimental peptide drug targeting obesity. It functions as a triple hormone receptor agonist, influencing metabolic regulation and appetite control. Notably effective in weight reduction, it’s a pioneering approach in obesity management, offering potential improvements in metabolic health.

Product Details

• Structure: Met-Arg-Trp-Gln-Glu-Met-Gly-Tyr-Ile-Phe-Tyr-Pro-Arg-Lys-Leu-Arg
• Molecular Formula: C101H152N28O22S2
• Molecular Weight: 2174.64 g/mol
• PubChem SID: 255386757
• CAS Number: 1627580-64-6
• Synonyms: Mitochondrial open reading frame of the 12S rRNA-c, MT-RNR1

Research Highlights

1. Retatrutide & Weight Loss: In a phase 2 trial, participants saw a mean weight reduction of 18% at 24 weeks and 24% at 48 weeks, surpassing placebo results.
2. Retatrutide & Glucose Metabolism: As a triple agonist, it positively influences glucose metabolism, beneficial in managing obesity-related impaired glucose regulation.
3. Retatrutide & Dose Response: The trial demonstrated a dose-response relationship, with higher doses leading to greater weight reduction, highlighting its customizable potential for obesity treatment.